



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$54.05

Change (%) ▲ 0.60 (1.12%)

Volume 122,209

Data as of September 22, 2017 4:02 p.m. ET

Management

Steven M. Klosk President and Chief Executive Officer

Shawn P. Cavanagh Executive Vice President and Chief Operating Officer

Samantha M. Hanley Vice President, General Counsel and Secretary

Gregory P. Sargen Executive Vice President, Corporate Development and Strategy

Tom Vadaketh Executive Vice President and Chief Financial Officer

Recent Headlines & Events

Date	Title	Date	Title
September 18, 2017	Cambrex to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference	September 25, 2017 9:10 a.m. ET	Cambrex at the 2017 Cantor Fitzgerald Global Healthcare Conference
August 30, 2017	Cambrex to Present at Upcoming Investor Conferences in September		
August 30, 2017	Cambrex Invests in New Analytical Development and Method Validation Laboratory at Its High Point, NC Facility		

SEC Filings

Filing Date	Form
September 05, 2017	4
August 04, 2017	10-Q
August 04, 2017	8-K
August 02, 2017	4

Data provided by Nasdaq. Minimum 15 minutes delayed.